Table 2.
Laboratory findings at admission between subjects with COPD and CPFE.
| Laboratory findings | Normal Range | Total (n = 259) | COPD (n = 207) | CPFE (n = 52) | P Value |
|---|---|---|---|---|---|
| Blood Routine | |||||
| Red blood cell count, × 1012/L | 3.80–5.10 | 3.97 (3.54–4.40) | 3.97 (3.56–4.40) | 3.91 (3.44–4.44) | 0.595 |
| Hemoglobin, g/L | 130–175 | 119.00 (103.00–131.00) | 119.00 (103.00–131.00) | 119.50 (106.00–132.00) | 0.646 |
| White blood cell count, × 109/L | 3.5–9.5 | 7.40 (5.60–9.70) | 7.60 (5.70–9.70) | 6.85 (4.85–8.85) | 0.168 |
| Neutrophil count, × 109/L | 1.8–6.3 | 5.30 (3.50–7.40) | 5.40 (3.60–7.50) | 4.70 (3.03–6.98) | 0.245 |
| Neut% | 40.0–75.0 | 71.40 (61.80–82.60) | 72.40 (62.20–83.10) | 68.25 (59.93–91.35) | 0.582 |
| Lymphocyte count, × 109/L | 1.1–3.2 | 1.20 (0.70–1.60) | 1.20 (0.70–1.60) | 1.10 (0.80–1.48) | 0.595 |
| Lymph% | 20.0–50.0 | 16.80 (9.00–24.90) | 16.60 (8.50–24.90) | 17.45 (10.95–25.38) | 0.522 |
| Eosinophil count, × 109/L | 0.02–0.52 | 0.10 (0.05–0.20) | 0.10 (0.04–0.20) | 0.20 (0.08–0.30) | 0.033 |
| Eos% | 0.4–8.0 | 1.40 (0.60–3.40) | 1.40 (0.50–3.00) | 2.10 (0.90–5.00) | 0.028 |
| Platelet count, × 109/L |
125–350 |
208.00 (158.00–273.00) |
215.00 (165.00–279.00) |
185.50 (136.50–232.00) |
0.025 |
| Blood Biochemistry | |||||
| Glucose, mmol/L | 3.9–5.8 | 5.50 (4.73–7.45) | 5.50 (4.78–7.45) | 5.60 (4.47–7.61) | 0.597 |
| Aspartate aminotransferase, U/L | 15.0–40.0 | 23.90 (18.60–32.15) | 23.85 (18.60–31.25) | 24.90 (18.20–34.60) | 0.632 |
| Alanine aminotransferase, U/L | 9.0–50.0 | 17.70 (11.85–29.25) | 17.85 (12.05–28.50) | 16.70 (11.50–35.80) | 0.640 |
| Lactate dehydrogenase, U/L | 120.0–250.0 | 210.00 (172.25–271.55) | 206.65 (169.63–266.50) | 226.50 (183.00–295.00) | 0.044 |
| Total bile acid, μmol/L | 0–12.0 | 3.80 (2.20–6.00) | 3.60 (2.00–5.90) | 4.10 (2.50–7.80) | 0.125 |
| Total bilirubin, μmol/L | 0–25.0 | 10.20 (7.40–14.40) | 9.75 (7.10–14.00) | 12.00 (8.50–14.50) | 0.045 |
| Albumin, g/L | 40.0–55.0 | 34.50 (30.50–38.50) | 34.50 (30.65–38.53) | 34.30 (30.40–38.50) | 0.742 |
| Blood uric acid, μmol/L | 208.0–428.0 | 315.89 ± 112.98 | 315.22 ± 116.61 | 318.55 ± 97.95 | 0.851 |
| Blood urea, mmol/L | 3.60–9.50 | 6.02 (4.63–7.66) | 6.03 (4.69–7.83) | 6.01 (4.28–7.54) | 0.620 |
| Serum creatinine, μmol/L | 41.0–111.0 | 77.00 (64.25–90.00) | 76.90 (64.08–90.78) | 77.20 (65.00–87.00) | 0.942 |
| C-reactive protein, mg/L | 0–8.00 | 21.70 (7.57–78.03) | 18.95 (7.68–77.75) | 28.00 (6.11–94.70) | 0.621 |
| Erythrocyte sedimentation rate, mm/h | 0–21 | 59.50 (35.00–88.00) | 60.00 (32.00–88.00) | 56.00 (41.00–104.00) | 0.105 |
| Complement C3, mg/L | 790.00–1520.00 | 922.44 ± 221.31 | 934.39 ± 220.30 | 877.96 ± 221.94 | 0.138 |
| Complement C4, mg/L | 100.00–400.00 | 254.14 ± 79.07 | 256.15 ± 77.74 | 246.61 ± 84.38 | 0.483 |
| Interleukin 6, pg/mL | <5.9 | 10.90 (5.08–28.23) | 11.30 (5.11–27.28) | 10.08 (4.30–35.35) | 0.917 |
| Tumor necrosis factor α, pg/mL | <8.1 | 10.70 (7.79–14.38) | 10.50 (7.67–13.70) | 11.50 (8.06–17.40) | 0.207 |
| Krebs von den Lungen-6, U/mL |
105.3–401.2 |
364.60 (253.10–606.80) |
339.30 (239.70–514.40) |
574.95 (344.48–941.60) |
<0.001 |
| Myocardial Injury Mediators | |||||
| Creatine kinase, U/L | 50.0–310.0 | 50.40 (31.98–77.83) | 52.85 (33.48–77.08) | 44.90 (27.00–92.35) | 0.495 |
| Myoglobin, μg/mL | <70 | 38.10 (26.63–55.90) | 36.45 (25.73–55.90) | 43.30 (31.23–55.98) | 0.214 |
| Creatine kinase-MB, U/L | <24.0 | 12.20 (9.20–16.25) | 12.30 (9.13–16.33) | 12.05 (9.30–16.33) | 0.871 |
| N-Terminal pro-brain natriuretic peptide (NT-proBNP), pg/mL |
0–450 |
309.49 (103.95–824.46) |
311.00 (119.00–861.26) |
287.67 (94.54–634.82) |
0.799 |
| Blood Coagulation | |||||
| D-dimer, μg/mL | 0–0.5 | 0.32 (0.16–0.85) | 0.31 (0.16–0.85) | 0.39 (0.16–0.88) | 0.706 |
| Prothrombin time (PT), s | 9.0–14.0 | 11.75 (11.00–12.60) | 11.70 (11.00–12.60) | 12.00 (11.00–13.20) | 0.123 |
| Activated partial thromboplastin time (APTT), s | 22.3–32.5 | 28.25 (26.50–31.68) | 28.15 (26.20–31.73) | 29.65 (26.88–31.60) | 0.229 |
| Prothrombin Time - International Normalized Ratio (PT-INR) |
0.8–1.2 |
0.99 (0.92–1.09) |
0.99 (0.92–1.09) |
1.02 (0.94–1.14) |
0.063 |
| Blood lipid | |||||
| Triglyceride, mmol/L | <1.70 | 1.14 (0.88–1.58) | 1.17 (0.88–1.60) | 1.12 (0.88–1.50) | 0.613 |
| Low density lipoprotein cholesterol, mmol/L | 1.55–3.19 | 2.66 (2.09–3.28) | 2.71 (2.09–3.33) | 2.55 (2.15–3.03) | 0.174 |
| Total cholesterol, mmol/L | <5.18 | 4.11 (3.33–4.99) | 4.22 (3.33–5.22) | 3.85 (3.32–4.56) | 0.136 |
| High density lipoprotein cholesterol, mmol/L | 1.04–1.55 | 0.94 (0.76–1.17) | 0.97 (0.78–1.21) | 0.86 (0.68–1.13) | 0.051 |
Data are presented as mean ± standard deviation (SD), medians (IQR) and n (%). P values were calculated by Student t-test, Mann–Whitney U test, as appropriate. P values indicate differences of characteristics between subjects with COPD and CPFE.